New approaches to the management of external genital warts

Infectious Diseases in Clinical Practice

Volumn 8, Issue 2, 1999, Pages 67-75

  Richwald, Gary A ^a   Reitano, Michael ^a  

^a LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DICHLOROACETIC ACID; FLUOROURACIL; IMIQUIMOD; INTERFERON; MESSENGER RNA; PODOPHYLLIN; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID; VIRUS DNA; VIRUS PROTEIN;

ALGORITHM; CANCER; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA; CRYOTHERAPY; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EROSION; ERYTHEMA; HUMAN; INFLAMMATION; NONHUMAN; PAIN; PHYSICAL EXAMINATION; PRURITUS; SHORT SURVEY; TOPICAL DRUG ADMINISTRATION; URETHROSCOPY; WART VIRUS;

EID: 0032907880     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199902000-00006     Document Type: Short Survey

References (37)

1. Reichman RC. Human papillomavirus infections. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill; 1998. p. 1098-100.
2. Tyring SK. Introduction: perspectives on human papillomavirus infection. Am J Med 1997;102:1-2.
3. Baker GE, Tyring SK. Therapeutic approaches to papillomavirus infections. Infect Dis Dermatol 1997;15:331-40.
4. Division of STD Prevention, U.S. Department of Health and Human Services. Sexually transmitted disease surveillance, 1996. Atlanta: Centers for Disease Control and Prevention, September 1997.
5. Beutner KR, Reitano MV, Richwald GA, et al. External genital warts: report of the American Medical Association Consensus Conference. AMA expert panel on external genital warts. Clin Infect Dis 1998;27:796-806.
6. Koutsky LA. Epidemiology of human papillomavirus infection. Am J Med 1997;102:3-8.
7. Handsfield HH, Hoel D. Sex, science, and society. Postgrad Med 1997;101:268-78.
8. Beutner KR, Tyring SK. Human papillomavirus and human disease. Am J Med 1997;102:9-15.
9. Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR 1997;47:88-95.
10. Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230-9.
11. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30.
12. Centers for Disease Control and Prevention. 1993 Sexually transmitted diseases treatment guidelines. MMWR 1993;42:78-80.
13. Beutner KR, Ferenczy A. Therapeutic approaches to genital warts. Am J Med 1997;102:28-37.
14. Strauss MJ, Khanna V, Koenig JD, et al. The cost of treating genital warts. Int J Dermatol 1996;35:340-8.
15. Stone KM. Human papillomavirus infection and genital warts: update on epidemiology and treatment. Clin Infect Dis 1995;20 Suppl 1:S91-7.
16. Conclylox® (podofilox) Topical Solution 0.5%. Physicians Desk Reference, 52nd ed. Montvale (NJ): Medical Economics Company; 1998. p 1925-6.
17. Condylox® Gel 0.5% (podofilox gel). Physicians Desk Reference, 52nd ed. Montvale (NJ): Medical Economics Company; 1998. p. 1924-5.
18. Tyring S, Edwards L, Cherry LK, et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998;134:53-8.
19. Aldara (imiquimod) Cream, 5%. Physicians Desk Reference, 52nd ed. Montvale (NJ): Medical Economics Company; 1998. p. 1522-4.
20. Handsfield HH. Clinical presentation and natural course of anogenital warts. Am J Med 1997-102: 16-20.
21. Vernon SD, Holmes KK, Reeves WC. Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21 Suppl 1:S121-4.
22. Verdon ME. Issues in the management of human papillomavirus genital disease. Am Fam Physician 1997;55: 1813-22.
23. Chopra K, Tyring SK. Human papillomavirus: a growing epidemic. Cortlandt Forum May 1997:264-9.
24. Stack PS. Pap smears. Postgrad Med 1997;101:207-14.
25. Ferenczy A. Human papillomavirus infections: current concepts, new developments. J SOGC 1997;19: 369-81.
26. Small RE, Honaker MR, Kennedy DT. Treating external genital warts. US Pharm 1998;11:117-26.
27. Kinghom GR, McMillan A, Mulcahy F, et al. An open, comparative study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS 1993;4:194-9.
28. Levien T, Baker DE. Imiquimod and tiludronate disodium. Hosp Pharm 1997;32:1658-67.
29. Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551-5.
30. Parmer JB, Basiliere EJ, Orenberg EK. Genital wart management: a partnership between physician and patient. Female Patient 1997;22:52-66.
31. Ordoukhanian E, Lane AT. Warts and molluscum contagiosum: beware of treatments worse than the disease. Postgrad Med 1997;101:223-35.
32. Taylor CA, Keller ML, Egan JJ. Advice from affected persons about living with human papillomavirus infection. Image J Nurs Sch 1997;29:27-32.
33. Clarke P, Ebel C, Catotti DN, et al. The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 1996;7:197-200.
34. Reynolds M, Murphy M, Waugh MA, et al. An audit of treatment of genital warts: opening the feedback loop. Int J STD AIDS 1993;4:226-31.
35. Reynolds M, Fraser PA, Lacey CT. Audits of the treatment of genital warts: closing the feedback loop. Int J STD AIDS 1996;7:347-52.
36. Richwald G. Treatment algorithm for external genital (anogenital) warts in Los Angeles County DHS STD Clinics. Sexually Transmitted Diseases Program, Los Angeles County Department of Health, 1998.
37. Reitano M. Counseling patients with genital warts. Am J Med 1997;102:38-43.